Ghana

in page functions
[French]
Ghana
Total population (2018) 29,280,222
Birth cohort (2018) 893,236
Surviving Infants (surviving to 1 year per year, 2018) 851,724
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 43/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 62/1000
World Bank Index, IDA (2015) 3.57
Gross Nation Income (per capita US$, 2015) 1,480
Co-financing group (2018) Preparatory transition
No. of districts/territories (2017) 216

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Ghana

Type of support

Approvals

2001-2022 (US$)
(20 Jul 2018)

Commitments

2001-2022 (US$)
(20 Jul 2018)

Disbursements

2000-2018 (US$)
(20 Jul 2018)

% Disbursed

(20 Jul 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $281,926,704 $305,034,854 $279,029,323
Cash Support (CASHSUPP) $170,000 $195,000 $170,000 100%
Civil Society Organisation support (CSO) $765,000 $765,000 $832,909 109%
Health system strengthening (HSS 1) $9,032,898 $9,032,898 $9,032,898 100%
Health system strengthening (HSS 2) $12,039,146 $18,919,296 $7,739,496 64%
HPV Demo (NVS) $188,885 $188,885 $190,108 101%
Immunisation services support (ISS) $5,316,620 $5,316,620 $5,316,620 100%
Injection Safety Devices (NVS) $946,000 $1,268,000 $1,149,807 122%
Injection safety support (INS) $855,300 $855,300 $855,300 100%
IPV (NVS) $1,101,768 $1,101,768 $738,356 67%
Measles (NVS) $1,711,336 $1,711,336 $1,711,336 100%
Measles-Rubella (NVS) $7,750,269 $7,750,269 $7,750,269 100%
Meningitis A (NVS) $1,735,548 $2,434,548 $1,787,414 103%
Meningitis A - campaign (NVS) $2,037,743 $2,037,743 $2,037,743 100%
Meningitis A - mini catch-up campaign (NVS) $635,266 $635,266 $635,266 100%
Meningitis A - mini catch-up op.costs (OPC) $524,500 $524,500 $524,500 100%
Meningitis A - operational costs (OPC) $1,949,753 $1,949,753 $1,949,753 100%
MR - Operational costs (OPC) $7,308,638 $7,308,638 $7,308,638 100%
MR-Follow-up campaign (NVS) $3,225,500 $3,225,500 $3,369,644 104%
MR-Follow-up campaign op.costs (OPC) $2,149,311 $2,149,311
Penta (NVS) $96,831,772 $98,699,272 $96,967,583 100%
Pneumo (NVS) $83,660,980 $92,739,480 $87,439,590 105%
Rotavirus (NVS) $26,307,937 $29,687,437 $25,627,041 97%
Vaccine Introduction Grant (VIG) $3,622,527 $3,622,527 $3,448,500 95%
Yellow Fever (NVS) $12,060,007 $12,916,507 $12,446,552 103%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Ghana DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 99%
M:F sex ratio at birth (2018) 1.05
Household survey: DTP3 coverage for male (2013) 86.80%
Household survey: DTP3 coverage for female (2013) 90.30%
Household survey: Last DTP3 survey (2013) 89%
% districts achieving > 80% DTP3 coverage (2017) 86%
% districts achieving < 50% DTP3 coverage (2017) 0%
MCV WHO/UNICEF estimates (2017) 95%

Breakdown of support

Non-vaccine support Vaccine support
13% 87%
$37,178,614 $241,850,709

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Ghana

09 May 2018

IFPW STEP

IFPW and Gavi expand leadership training for a stronger supply chain

The partnership draws on private sector support to implement an innovative training and mentorship programme for supply chain managers in Gavi-supported countries.

23 May 2017

Seth Q&A

Big Ideas: Gavi CEO Seth Berkley's Q&A, Part II

Ahead of Seth Berkley’s speech to the 2017 graduating class at Johns Hopkins University in Washington, DC on 23 June, Global Health published a two-part Q&A with the Gavi CEO. In this second article, Seth shares his concerns about the expansion of the vaccine hesitancy movement, explains why digital identity technologies in low- and middle-income countries can help improve vaccine coverage, and discusses the value of testing the potentially important malaria vaccine.

24 April 2017

Mosquito malaria

Partnership supports launch of malaria vaccine pilots in three African countries

Funders hail next step in the development of world’s first malaria vaccine.

close icon

modal window here